Deucrictibant, Placebo
Phase 3CompletedDevelopment Stage
Hereditary Angioedema
Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor [C1-INH] Deficiency, C1 Esterase Inhibitor Deficiency, C1 Esterase Inhibitor, Deficiency of, C1 Inhibitor Deficiency, Hereditary Angioedema - Type 3, Hereditary Angioedema Type III
Feb 26, 2024 → Oct 17, 2025
About Deucrictibant, Placebo
Deucrictibant, Placebo is a phase 3 stage product being developed by Pharvaris for Hereditary Angioedema. The current trial status is completed. This product is registered under clinical trial identifier NCT06343779. Target conditions include Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II.
What happened to similar drugs?
2 of 20 similar drugs in Hereditary Angioedema were approved
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06343779 | Phase 3 | Completed |
Competing Products
20 competing products in Hereditary Angioedema
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KVD900 | KalVista Pharmaceuticals | Phase 2 | 29 |
| KVD824 + Placebo to KVD824 | KalVista Pharmaceuticals | Phase 1 | 23 |
| KVD900 600 mg + KVD900 300 mg | KalVista Pharmaceuticals | Phase 3 | 38 |
| Sebetralstat | KalVista Pharmaceuticals | Pre-clinical | 20 |
| KVD900 + Placebo to KVD900 | KalVista Pharmaceuticals | Phase 1 | 23 |
| Sebetralstat | KalVista Pharmaceuticals | Pre-clinical | 24 |
| Placebo + KVD900 600 mg + KVD900 300 mg | KalVista Pharmaceuticals | Phase 3 | 34 |
| KVD824 Prototype 1 modified-release tablet + KVD824 Prototype 2 modified-release tablet + KVD824 Immediate-Release Capsule + Placebo to KVD824 Prototype 1 + KVD824 Prototype 3 modified-release tablet | KalVista Pharmaceuticals | Phase 1 | 23 |
| KVD900 150 mg + KVD900 300 mg + KVD900 600 mg | KalVista Pharmaceuticals | Phase 3 | 34 |
| KVD824 + Placebo to KVD824 | KalVista Pharmaceuticals | Phase 2 | 21 |
| KVD900 600 mg + Drug: KVD900 300 mg | KalVista Pharmaceuticals | Phase 3 | 38 |
| Deferasirox FCT | Novartis | Phase 2 | 27 |
| Canakinumab + Placebo | Novartis | Phase 3 | 40 |
| Ilaris | Novartis | Pre-clinical | 33 |
| Standard of Care for Haemophilia A | Roche | Pre-clinical | 26 |
| Emicizumab | Roche | Phase 3 | 40 |
| Tafamidis | Pfizer | Pre-clinical | 26 |
| tafamidis | Pfizer | Pre-clinical | 26 |
| Nitisinone | Swedish Orphan Biovitrum | Pre-clinical | 26 |
| Nitisinone | Swedish Orphan Biovitrum | Phase 1 | 29 |